Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEBAug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Home - Clinical Trials Arena
WEBMpox: Three ongoing vaccine trials to watch. As the World Health Organization (WHO) has declared mpox an emergency, the Clinical Trials Arena team investigates ongoing vaccine trials.
Obesity: Six trials to watch over the next 12 months
WEBJun 30, 2023 · According to a report by GlobalData, the market for obesity drugs is predicted to be worth $37.1bn in 2031. GlobalData is a parent company of the Clinical Trials Arena. As more trials take place globally, not only will this help to provide a wider range of treatments for patients but will also assist the unmet need of lack of supply.
Merck releases new data on sotatercept in PAH - Clinical Trials Arena
WEBSep 12, 2023 · Merck (MSD) released new data analyses from two trials investigating sotatercept for adults with pulmonary arterial hypertension (PAH). MSD presented the data at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy, on 9-13 September. Sotatercept is a potential first-in-class activin signalling inhibitor.
Pfizer hidradenitis suppurativa trial completion boosts shot at …
WEBFeb 15, 2022 · Pfizer ’s PF-06650833 (zimlovisertib) for hidradenitis suppurativa saw its PTSR rise nine points to 33% after its Phase II trial was completed. Its ClinicalTrials.gov page was updated to “completed” on 4 February, and the PTSR change took effect 7 February. The placebo-controlled Phase II (NCT04092452) …
Artivion strengthens On-X heart valve data with real-world study
WEBOct 6, 2023 · Real-world data of Artivion’s On-X heart valve showed reduced mortality and bleeding events with a low dose of warfarin therapy. Phalguni Deswal October 6, 2023. On-X is a high-grossing product for Artivion and generated $35.6m in sales in H1 2023. Image Credit: Natali _ Mis / Shutterstock. Artivion presented data from the post-market study ...
About Us Online - Clinical Trials Arena
WEBAbout Us. Clinicaltrialsarena.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone – from senior management through to research and QA ...
News - Clinical Trials Arena
WEBIpsen shelves Cabometyx combo in prostate cancer after Phase III miss. One of Ipsen’s flagship oncology assets Cabometyx (cabozantinib) will not be gaining an indication in prostate cancer outside the US…. Robert Barrie. News.
CRO consolidation: is the clinical trials industry reaching a tipping ...
WEBNov 2, 2022 · Labcorp announced the spinoff of its drug development and clinical trials arm in August 2022, called Clinical Development Business, which will now operate as a CRO offering Phase I–IV clinical trial management and technology to the biopharma industry. Labcorp will retain the laboratory business that is related to routine and esoteric labs, central labs, and early development research labs.
Outsourcing trends in clinical trials: How one company is …
WEBSep 18, 2023 · George Sawicki (GS): There is certainly a gravitational pull to the FSP model. Many larger FSP players have now been acquired by CROs, which has made them even bigger. We’ve noticed a lot more traction for a company that’s our size; companies that use more of a boutique shop while always ensuring the number one priority is quality.